BIO:NYE-Bio-Rad Laboratories Inc (USD)

COMMON STOCK | Medical Devices |

Last Closing

USD 330.58

Change

-1.06 (-0.32)%

Market Cap

USD 9.26B

Volume

0.22M

Analyst Target

USD 525.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets. It also designs, manufactures, markets, and supports test systems, informatics systems, test kits, and specialized quality controls for hospitals, diagnostic reference, transfusion, and physician office laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California. Address: 1000 Alfred Nobel Drive, Hercules, CA, United States, 94547

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-30 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
ABT Abbott Laboratories

+1.05 (+0.93%)

USD 199.13B
MDT Medtronic PLC

+0.18 (+0.20%)

USD 118.35B
STE STERIS plc

+0.52 (+0.23%)

USD 21.85B
ZBH Zimmer Biomet Holdings Inc

+5.93 (+5.71%)

USD 21.23B
SNN Smith & Nephew SNATS Inc

-0.02 (-0.07%)

USD 12.71B
GMED Globus Medical

+0.78 (+1.05%)

USD 10.01B
BIO-B Bio-Rad Laboratories Inc

N/A

USD 9.19B
PEN Penumbra Inc

+1.66 (+0.79%)

USD 7.95B
GKOS Glaukos Corp

+0.93 (+0.68%)

USD 7.18B
INSP Inspire Medical Systems Inc

-2.54 (-1.28%)

USD 5.82B

ETFs Containing BIO

SYNB Putnam Biorevolution ETF 5.26 % 0.00 %

+0.03 (+0.33%)

USD 5.72M
MOTU:LSE VanEck Morningstar US Wid.. 2.64 % 0.00 %

+0.08 (+0.33%)

USD 0.05B
MOAT:AU VanEck Morningstar Wide M.. 2.58 % 0.00 %

+0.01 (+0.33%)

USD 0.98B
MHOT:AU VanEck Morningstar Wide M.. 2.52 % 0.00 %

N/A

N/A
GERM 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -48.81% 35% F 10% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -48.81% 35% F 16% F
Trailing 12 Months  
Capital Gain -40.44% 35% F 10% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -40.44% 35% F 16% F
Trailing 5 Years  
Capital Gain -53.09% 46% F 13% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -53.09% 50% F 21% F
Average Annual (5 Year Horizon)  
Capital Gain -3.07% 35% F 21% F
Dividend Return -3.07% 32% F 12% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 35.48% 42% F 28% F
Risk Adjusted Return -8.65% 29% F 17% F
Market Capitalization 9.26B 78% C+ 85% B

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector